Novel Targeted Therapy for EGFR Exon 20–Positive NSCLC
Comprehensive insight on the two novel, targeted agents approved for the management of EGFR exon 20–positive NSCLC following frontline therapy.
Case: A 59-Year-Old Female with Lung Cancer
Initial presentation
- BC is a 59 y/o Asian female who presents to her physician complaining of shortness of breath, fatigue, and persistent right- sided neck pain.
- BC believes she is experiencing neck pain because of her new sleeping pillow.
- Since her last examination 6 months ago, BC has lost close to 10 lbs. BC has not changed her eating habits or style.
- PMH: Hypercholesterolemia (controlled)
- SMH: no history of smoking; drinks socially
- FH: she lives with her partner and 2 dogs; mother passed away from ovarian cancer 3 years ago.
- PE: LLL auscultation reveals decreased breath sounds visible bruising
Clinical workup
- Current Labs:
- CBC panel: Normal
- Liver function/Renal function: Normal
- CT Chest: LLL primary, mediastinal LNs; bone metastases
- Diagnosis: Stage IV adenocarcinoma
- MRI brain is negative for brain metastases
- CT scan of abdomen and pelvis shows additional bone metastases
- Weight: 120 lbs (54.5 kg)
- Biopsy of mediastinal lymph nodes shows stage 4 lung adenocarcinoma
- PD-L1 55%
Treatment
- NGS has been ordered and the results are pending.
- Patient initiated on a chemotherapy doublet.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
